Plain-English translation of NCT06377566 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether (BV) combined with three standard chemotherapy drugs works better than chemotherapy alone for people with newly diagnosed Hodgkin lymphoma that has large tumors. is a special type of drug that targets cancer cells by latching onto a protein called CD30 found on lymphoma cells, then delivering treatment directly into those cells. The hope is that this combination will be more effective at stopping the cancer's growth.
Current treatments for this type of early-stage, bulky lymphoma can work, but doctors want to see if adding the new medication improves outcomes and helps more patients achieve complete remission.
You likely qualify if…
You likely don't qualify if…
You would receive four to six cycles of the medication combination, with each cycle spaced about three to four weeks apart (based on standard chemotherapy timing). After your first two cycles, you'll have a PET scan to check how well the treatment is working, and your care plan may be adjusted based on those results. Some patients may also receive radiation therapy depending on their scan results and tumor size. Throughout treatment, you'll have regular blood tests and doctor visits to monitor how you're tolerating the medication.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States